Tinnitus Is Associated with a Higher Risk of Benign Brain Tumors: A Nationwide, Population-Based Secondary Cohort Study of Young and Middle-Aged AdultsChen J.-C.a,b · Koo M.c,d · Hwang J.-H.b,e
aDepartment of Neurosurgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
bSchool of Medicine, Tzu Chi University, Hualien, Taiwan
cDepartment of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
dDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
eDepartment of Otolaryngology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: It remains unclear whether tinnitus is associated with a higher risk of benign or malignant brain tumors in humans. Therefore, the aim of this secondary study was to investigate the risk of brain tumors in adult with tinnitus using data from a nationwide health claims research database. Methods: Patients aged 20–50 years who were newly diagnosed with tinnitus were identified from the Taiwan’s National Health Insurance Research Database and they served as the study cohort. A comparison cohort was formed by using patients without tinnitus from the same database with frequency matching (4: 1) by 10-year age interval and gender to the patients in the tinnitus cohort. Cox proportional hazards models were used to calculate the adjusted hazard ratios (AHR) for benign and malignant brain tumors in patients with tinnitus, adjusting for age, gender, and comorbidities. Results: There were 15,819 patients in the tinnitus cohort and 63,276 in the comparison cohort. A significantly higher proportion of patients with tinnitus had benign brain tumor (p = 0.003) and all 11 comorbid conditions (p < 0.001) compared to those without tinnitus. Cox proportional hazards regression analysis performed on the basis of age, gender, and the 11 comorbidities revealed that tinnitus was independently associated with a higher risk for benign brain tumor (AHR 1.65, 95% CI 1.24–2.20, p = 0.001) and but not with malignant brain tumors (AHR 1.66, 95% CI 0.93–2.94, p = 0.085). Conclusions: Findings from this secondary cohort analysis indicated that tinnitus is associated with a higher risk of benign brain tumors.
© 2017 S. Karger AG, Basel
- Langguth B, Kreuzer PM, Kleinjung T, De Ridder D: Tinnitus: causes and clinical management. Lancet Neurol 2013; 12: 920–930.
- Xu X, Bu X, Zhou L, Xing G, Liu C, Wang D: An epidemiologic study of tinnitus in a population in Jiangsu Province, China. J Am Acad Audiol 2011; 22: 578–585.
- Beebe Palumbo D, Joos K, De Ridder D, Vanneste S: The management and outcomes of pharmacological treatments for tinnitus. Curr Neuropharmacol 2015; 13: 692–700.
- Møller AR: Pathophysiology of tinnitus. Otolaryngol Clin North Am 2003; 36: 249–266.
- Issa M, Bisconti S, Kovelman I, Kileny P, Basura GJ: Human auditory and adjacent nonauditory cerebral cortices are hypermetabolic in tinnitus as measured by functional near-infrared spectroscopy (fNIRS). Neural Plast 2016; 2016: 7453149.
- Knipper M, Zimmermann U, Muller M: Molecular aspects of tinnitus. Hear Res 2010; 266: 60–69.
- Yew KS: Diagnostic approach to patients with tinnitus. Am Fam Physician 2014; 89: 106–113.
- Kazmierczak H, Doroszewska G: Metabolic disorders in vertigo, tinnitus, and hearing loss. Int Tinnitus J 2001; 7: 54–58.
- Pinto PC, Marcelos CM, Mezzasalma MA, Osterne FJ, de Melo Tavares de Lima MA, Nardi AE: Tinnitus and its association with psychiatric disorders: systematic review. J Laryngol Otol 2014; 128: 660–664.
- Lee SH, Choi SK, Lim YJ, Chung HY, Yeo JH, Na SY, Kim SH, Yeo SG: Otologic manifestations of acoustic neuroma. Acta Otolaryngol 2015; 135: 140–146.
- Ikegami-Takada T, Izumikawa M, Doi T, Takada Y, Tomoda K: AICA syndrome with facial palsy following vertigo and acute sensorineural hearing loss. Auris Nasus Larynx 2012; 39: 244–248.
- Sugiura S, Uchida Y, Nakashima T, Yoshioka M, Ando F, Shimokata H: Tinnitus and brain MRI findings in Japanese elderly. Acta Otolaryngol 2008; 128: 525–529.
- Galazyuk AV, Wenstrup JJ, Hamid MA: Tinnitus and underlying brain mechanisms. Curr Opin Otolaryngol Head Neck Surg 2012; 20: 409–415.
- Rankin EB, Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678–685.
- Jensen RL: Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92: 317–335.
- Ismail HM: Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients’ survival. J Oncol 2012; 2012: 416927.
- Chen JC, Hwang JH: Sleep apnea increased incidence of primary central nervous system cancers: a nationwide cohort study. Sleep Med 2014; 15: 749–754.
- Lopez-Escamez JA, Bibas T, Cima RF, Van de Heyning P, Knipper M, Mazurek B, Szczepek AJ, Cederroth CR: Genetics of tinnitus: an emerging area for molecular diagnosis and drug development. Front Neurosci 2016; 10: 377.
- Gilles A, Van Camp G, Van de Heyning P, Fransen E: A pilot genome-wide association study identifies potential metabolic pathways involved in tinnitus. Front Neurosci 2017; 11: 71.
- Martin DM, Raphael Y: Gene-based diagnostic and treatment methods for tinnitus. Int Tinnitus J 2003; 9: 3–10.
- Wrensch M, Minn Y, Chew T, Bondy M, Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002; 4: 278–299.
- McNeill KA: Epidemiology of brain tumors. Neurol Clin 2016; 34: 981–998.
- Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS: The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol 2014; 16: 896–913.
- Koo M, Hwang JH: Risk of tinnitus in patients with sleep apnea: a nationwide, population-based case control study. Laryngoscope 2016; 127: 2171–2175.
- Hu J, Chen Z, Gorczynski CP, Gorczynski LY, Kai Y, Lee L, Manuel J, Gorczynski RM: Sleep-deprived mice show altered cytokine production manifest by perturbations in serum IL-1ra, TNFa, and IL-6 levels. Brain Behav Immun 2003; 17: 498–504.
- Hwang JH, Chen JC, Yang SY, Wang MF, Chan YC: Expression of tumor necrosis factor-alpha and interleukin-1beta genes in the cochlea and inferior colliculus in salicylate-induced tinnitus. J Neuroinflammation 2011; 8: 30.
- Hwang JH, Chen JC, Chan YC: Effects of C-phycocyanin and Spirulina on salicylate-induced tinnitus, expression of NMDA receptor and inflammatory genes. PLoS One 2013; 8:e58215.
- Hwang JH, Chen JC, Yang SY, Wang MF, Liu TC, Chan YC: Expression of COX-2 and NMDA receptor genes at the cochlea and midbrain in salicylate-induced tinnitus. Laryngoscope 2011; 121: 361–364.
- Hwang JH, Chang NC, Chen JC, Chan YC: Expression of antioxidant genes in the mouse cochlea and brain in salicylate-induced tinnitus and effect of treatment with Spirulina platensis water extract. Audiol Neurootol 2015; 20: 322–329.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.